Skip to main content

Advertisement

SpringerLink
Log in

Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zanotti-Fregonara P, Rubello D, Hindié E. Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. Eur J Nucl Med Mol Imaging 2008;35:1397–1399.

    Article  PubMed  Google Scholar 

  2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.

    Article  PubMed  CAS  Google Scholar 

  3. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941–1959.

    Article  PubMed  CAS  Google Scholar 

  4. Schlumberger M, Ricard M, De Pouvourville G, Pacini F. How the availability of human TSH has changed the management of patients who have thyroid cancer. Nat Clin Pract Endocrinol Metab 2007;3:641–650.

    Article  PubMed  Google Scholar 

  5. Hänscheid H, Lassmann M, Luster M, Thomas S, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648–654.

    PubMed  Google Scholar 

  6. Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J, et al. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 2008;49:1445–1450.

    Article  PubMed  CAS  Google Scholar 

  7. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007;156:531–538.

    Article  PubMed  CAS  Google Scholar 

  8. Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormones and Thyrogen. Eur J Nucl Med Mol Imaging 2008;35:1457–1463.

    Article  PubMed  CAS  Google Scholar 

  9. Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and pharmaco-economic comparison to recombinant thyrotropin administration. Thyroid 2005;15:1147–1155.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Ulm, Albert-Einstein-Str. 23, 89081, Ulm, Germany

    Markus Luster

  2. Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Rousy, 94805, Villejuif Cédex, France

    Martin Schlumberger

  3. Department of Internal Medicine, Section of Endocrinology & Metabolism, University of Siena, 46-53100, Siena, Italy

    Furio Pacini

Authors
  1. Markus Luster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Schlumberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Furio Pacini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Luster.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Luster, M., Schlumberger, M. & Pacini, F. Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. Eur J Nucl Med Mol Imaging 36, 329–330 (2009). https://doi.org/10.1007/s00259-008-1013-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-1013-9

Keywords

Search

Navigation